Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and TACE for Pulmonary Metastasis of Hepatocellular Carcinoma
NCT02702323Phase 3Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of Rivoceranib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02702323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702323.